Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The 50-bed hospital is positioned to address complexities specific to women and children, going beyond a birthing facility
Acute therapies continue to report strong growth compared to chronic ones.
It recommends using the vaccine to prevent the spread of the disease
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
The company is eligible for 12 months exclusivity from launch
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Subscribe To Our Newsletter & Stay Updated
